Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 3

Novel conditioning regimens for bone marrow transplantation

Authors Shi M, Li M, Ikehara S

Received 16 October 2012

Accepted for publication 29 November 2012

Published 8 January 2013 Volume 2013:3 Pages 1—9

DOI https://doi.org/10.2147/BLCTT.S26390

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3



Ming Shi, Ming Li, Susumu Ikehara

Department of Stem Cell Disorders, Kansai Medical University, Moriguchi City, Osaka, Japan

Abstract: Bone marrow transplantation (BMT) has evolved into an effective strategy for the treatment of hematological and oncological disorders. Radiotherapy and chemotherapy are used as conditioning regimens prior to BMT to suppress host immunity and reduce tumor burden. High doses of total body irradiation are conventionally administered along with alkylating agents, ie, the myeloablative regimen, to help ensure rapid engraftment of donor cells and to prevent relapse. However, the toxicity of the myeloablative conditioning regimen and unacceptable nonrelapse mortality rules out this approach for older patients by whom less intense preparative regimens are likely to be better tolerated. The reduced-intensity and nonmyeloablative conditioning regimens have been demonstrated by many investigators to be novel approaches resulting in a lower nonrelapse mortality rate and lower incidence of severe acute graft versus host disease. Here, we review the conditioning regimens employed as a pretreatment for BMT, and focus on the novel conditioning regimens and cutting edge developments.

Keywords: myeloablative conditioning regimen, reduced-intensity conditioning, nonmyeloablative conditioning regimen, relapse, nonrelapse mortality, graft versus host disease

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.